<DOC>
	<DOCNO>NCT02242279</DOCNO>
	<brief_summary>Study investigate dose-dependent bronchodilator effect safety single inhalation dos BEA 2180 inhale via Respimat® compare placebo patient stable Chronic Obstructive Pulmonary Disease ( COPD )</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Inhaled BEA 2180 BR COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . All patient sign date inform consent consistent International committee harmonisation ( ICH ) Good Clinical Practice ( GCP ) guideline prior participation trial , include medication washout restriction 2 . All patient must diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients must relatively stable , moderate severe airway obstruction FEV1 ≤ 60 % predict normal FEV1 ≤ 70 % FVC ( Visits 1 2 ) 3 . All patient must increase FEV1 least 12 % baseline 45 min inhalation 80 μg ipratropium inhale via Hydro Fluoro Alkane ( HFA ) Metered Dose Inhaler ( MDI ) 4 . Male female patient 40 year age old . Female patient child bear potential could participate study 5 . Patients must current exsmokers smoke history 10 pack/years ( Patients never smoke cigarette must exclude ) 6 . Patients must able perform technically acceptable pulmonary function test inhale medication competent manner Respimat® device HandiHaler® 1 . Patients significant disease Chronic Obstructive Pulmonary Disease ( COPD ) must exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study 2 . Patients clinically relevant abnormal baseline hematology , blood chemistry , urinalysis , abnormality defines significant disease 3 . Patients significant prostatic hyperplasia 4 . Patients recent history ( i.e . one year less ) myocardial infarction 5 . Patients unstable lifethreatening cardiac arrhythmia patient hospitalized event within past year 6 . Patients history ( less 3 year ) cardiac failure , cor pulmonale cardiac arrhythmia require drug therapy 7 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . Patients treat basal cell carcinoma allow 8 . Patients know narrowangle glaucoma 9 . Patients history asthma , allergic rhinitis total blood eosinophil count ≥ 600/mm3 . A repeat eosinophil count conduct patient 10 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis 11 . Patients know active tuberculosis 12 . Patients history and/or active significant alcohol drug abuse 13 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason must exclude 14 . Patients complete pulmonary rehabilitation program six week prior Screening Visit ( Visit 1 ) 15 . Patients regularly use daytime oxygen therapy 16 . Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit ( Visit 1 ) 17 . Patients treat oral betaadrenergic 18 . Patients treat betablockers 19 . Patients treat cromolyn sodium nedocromil sodium 20 . Patients treated antihistamine ( H1 receptor antagonist ) , antileukotrienes leukotriene receptor antagonist asthma exclude allergic condition 21 . Patients use oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day 22 . Patients know hypersensitivity anticholinergic drug , betaadrenergic , lactose component medication delivery system 23 . Pregnant nursing woman woman childbearing potential . Female patient either : Surgically sterilize hysterectomy bilateral tubal ligation Postmenopausal least two year 24 . Patients previous participation ( receipt randomize treatment ) study 25 . Patients participate another study 26 . The randomization patient respiratory infection COPD exacerbation six week prior Screening Visit ( Visit 1 ) baseline period must postpone . Patients could randomize six week follow recovery infection exacerbation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>